^
    Back
    Association details:
    Biomarker:RET rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Sunitinib in Never-Smokers With Lung Adenocarcinoma

    Excerpt:
    ...Must have < 100 cigarettes smoked lifetime OR known to harbor a RET rearrangement...
    Trial ID:
    NCT01829217
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

    Excerpt:
    ...sunitinib was initially dosed at a starting dose of 50 mg daily, the protocol was amended to permit a starting dose of 37.5 mg daily based on clinical judgment....Of the thirteen patients, 7 harbored RET rearrangements; none of these patients had an objective response while 5 (71%) demonstrated stable disease and 2 (29%) had progressive disease….
    DOI:
    10.1158/1078-0432.CCR-20-0397
    Trial ID:
    NCT01829217